Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19476925 | 0.70 | NR1H2 (0.36) | NR1H2 | |
| SCHEMBL22399904 | 0.66 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL20755921 | 0.66 | BRD4 (0.33) | ALDH1A1NR1H2 | |
| SCHEMBL18520816 | 0.64 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL18510373 | 0.63 | GABRA1 (0.35) | — | |
| SCHEMBL20756060 | 0.63 | ADORA2A (0.34) | — | |
| SCHEMBL22326777 | 0.61 | ALDH1A1 (0.39) | ALDH1A1NR1H2 | |
| SCHEMBL22349704 | 0.61 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL22547338 | 0.61 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL21137236 | 0.60 | ADORA3 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | ALDH1A1 3598/4885NR1H2 3044/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | ALDH1A1 3598/4885NR1H2 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.